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Background
A3R5 is a highly sensitive cell line for the detection of neu-
tralizing antibodies (Nabs) against tier 2 strains of HIV-1.
This cell line is particularly useful for the detection of
weak Nab responses in preclinical and clinical trials of
candidate HIV-1 vaccines. All methods used for endpoint
analyses in clinical trials should be validated and demon-
strably fit for purpose, in compliance with ICH Q2 (R1)
guidelines. Here we describe the optimization/qualification
and validation of the HIV-1 Nab Assay in A3R5 cells.
Methods
A3R5 is a human lymphoblastoid cell line naturally
expressing CD4 and CXCR4 and engineered to express
CCR5. Nab assays in A3R5 cells are performed with Env.
IMC.LucR viruses containing a reporter gene in the viral
genome, whose expression is induced by viral Tat protein
soon after infection. Luciferase activity is quantified by
luminescence and is directly proportional to the number
of infectious virus particles present in the viral inoculum.
The assay is performed in 96-well culture plates for high
throughput capacity.
Results
We determined the stability of the cell line over time in
culture for receptor and coreceptor expression, suscept-
ibility to infection, and sensitivity to neutralization. The
assay was optimized for cell density, input virus dose,
length of incubation time and use of DEAE-dextran. We
also determined the stability of a set of reference reagents,
for validation experiments and for future competency and
proficiency testing that express a broad spectrum of neu-
tralization phenotypes. A prospective validation plan with
pre-set pass/fail criteria was composed and implemented
that addressed key assay parameters, including accuracy,
precision, limit of detection and quantitation, specificity,
linearity and range, robustness and specificity. Results of
validation experiments were statistically analyzed and used
to generate a final validation document.
Conclusion
This validated assay will be used to identify correlates of
protection in HIV vaccine trials conducted globally.
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